Pharma industry keeps spending more on lobbying

12 August 2019

An investigation from transparency nonprofit Center for Responsive Politics has found that the pharmaceutical and health products industry is “consistently near the top” of sectors spending on federal campaign contributions.

Through its website OpenSecrets.org, the group seeks to track spending in US politics, relying on financial support from institutional grants, individual contributions and custom research.

Last year the industry spent a record-breaking total of $283 million on lobbying, including from the Pharmaceutical Research & Manufacturers of America (PhRMA), which spent $27 million on behalf of its members.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK